Intracellular Glucose‐Depriving Polymer Micelles for Antiglycolytic Cancer Treatment
Source abstract
Abstract
Abstract A new anticancer strategy to exploit abnormal metabolism of cancer cells rather than to merely control the drug release or rearrange the tumor microenvironment is reported. An antiglycolytic amphiphilic polymer, designed considering the unique metabolism of cancer cells (Warburg effect) and aimed at the regulation of glucose metabolism, is synthesized through chemical conjugation between glycol chitosan (GC) and phenylboronic acid (PBA). GC‐PBA derivatives form stable micellar structures under physiological conditions and respond to changes in glucose concentration. Once the micelles accumulate at the tumor site, intracellular glucose capture occurs, and the resultant energy deprivation through the inhibition of aerobic glycolysis remarkably suppresses tumor growth without significant side effects in vivo. This strategy highlights the need to develop safe and effective cancer treatment without the use of conventional anticancer drugs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer, Hypoxia, and Metabolism · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering and Institute of Nano Science and Technology Hanyang University Seoul 04763 Republic of Korea
Biotherapeutics Translational Research Center Korea Research Institute of Bioscience and Biotechnology Daejeon 34141 Republic of Korea
Department of Biomolecular Science KRIBB School of Bioscience Korea University of Science and Technology Daejeon 34113 Republic of Korea
College of Pharmacy Graduate School of Pharmaceutical Sciences Ewha Womans University Seoul 03760 Republic of Korea
Medicinal Materials Research Center Biomedical Research Division Korea Institute of Science and Technology Seoul 02792 Republic of Korea
KU‐KIST Graduate School of Converging Science and Technology Korea University Seoul 02841 Republic of Korea
References (55)
Show source-provided references
1. 10.1016/j.actbio.2021.01.00310.1016/j.actbio.2021.01.003 ↗
2. 10.3389/fphar.2020.0073310.3389/fphar.2020.00733 ↗
3. 10.1016/j.drudis.2019.12.00310.1016/j.drudis.2019.12.003 ↗
4. 10.1016/j.carres.2021.10836810.1016/j.carres.2021.108368 ↗
5. 10.1016/j.bbagen.2019.06.00710.1016/j.bbagen.2019.06.007 ↗
6. 10.1016/j.bbcan.2021.18858510.1016/j.bbcan.2021.188585 ↗
7. 10.3389/fimmu.2021.65636410.3389/fimmu.2021.656364 ↗
8. 10.1007/s10565-019-09461-z10.1007/s10565-019-09461-z ↗
9. 10.3389/fimmu.2018.0315410.3389/fimmu.2018.03154 ↗
10. 10.1016/j.ijpharm.2017.11.00310.1016/j.ijpharm.2017.11.003 ↗
11. 10.3390/ijms2212658710.3390/ijms22126587 ↗
12. 10.1038/nrc281710.1038/nrc2817 ↗
13. 10.1038/s42255-020-0172-210.1038/s42255-020-0172-2 ↗
14. 10.1039/C7TB03332J10.1039/C7TB03332J ↗
15. 10.3390/molecules2602027210.3390/molecules26020272 ↗
16. 10.3390/polym1323421910.3390/polym13234219 ↗
17. 10.1021/acs.biomac.8b0150810.1021/acs.biomac.8b01508 ↗
18. 10.1039/D1TB00880C10.1039/D1TB00880C ↗
19. 10.1016/j.jconrel.2009.01.01810.1016/j.jconrel.2009.01.018 ↗
20. 10.1016/j.jconrel.2021.02.01610.1016/j.jconrel.2021.02.016 ↗
21. 10.1007/978-3-319-77736-8_110.1007/978-3-319-77736-8_1 ↗
22. 10.1038/cddis.2017.19210.1038/cddis.2017.192 ↗
23. 10.1128/MCB.00479-1610.1128/MCB.00479-16 ↗
24. 10.1016/j.celrep.2015.01.02010.1016/j.celrep.2015.01.020 ↗
25. 10.1016/j.jconrel.2017.09.01510.1016/j.jconrel.2017.09.015 ↗
26. 10.1016/j.bios.2019.05.01910.1016/j.bios.2019.05.019 ↗
27. Ahmadi‐Naji R. · Avicenna J. Phytomed. · 2017 · 7 · 454
28. 10.1016/j.biomaterials.2017.04.04310.1016/j.biomaterials.2017.04.043 ↗
29. 10.1016/j.semcancer.2018.10.00210.1016/j.semcancer.2018.10.002 ↗
30. 10.3390/ijms2006126310.3390/ijms20061263 ↗
31. 10.1016/j.drup.2017.05.00210.1016/j.drup.2017.05.002 ↗
32. 10.1016/j.bbcan.2021.18856310.1016/j.bbcan.2021.188563 ↗
33. 10.2174/138920021666615060214514510.2174/1389200216666150602145145 ↗
34. 10.1126/scisignal.aam789310.1126/scisignal.aam7893 ↗
35. 10.1016/j.ceb.2006.10.00510.1016/j.ceb.2006.10.005 ↗
36. 10.3390/molecules2619604210.3390/molecules26196042 ↗
37. 10.1021/acsmedchemlett.0c0003110.1021/acsmedchemlett.0c00031 ↗
38. Han X.‐M. · Am. J. Transl. Res. · 2020 · 12 · 1515
39. 10.1016/j.jconrel.2015.08.05010.1016/j.jconrel.2015.08.050 ↗
40. 10.1186/s12951-018-0398-210.1186/s12951-018-0398-2 ↗
41. 10.3389/fmolb.2020.61053310.3389/fmolb.2020.610533 ↗
42. 10.1016/j.semcdb.2017.07.02210.1016/j.semcdb.2017.07.022 ↗
43. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
44. 10.1016/j.jcmgh.2020.10.01010.1016/j.jcmgh.2020.10.010 ↗
45. 10.1016/j.freeradbiomed.2019.09.02010.1016/j.freeradbiomed.2019.09.020 ↗
46. Zhu J. · Am. J. Transl. Res. · 2016 · 8 · 4812
47. Walia S. · 2016
48. 10.3390/pharmaceutics1208070110.3390/pharmaceutics12080701 ↗
49. 10.3390/polym1206139710.3390/polym12061397 ↗
50. 10.1039/D0TB00357C10.1039/D0TB00357C ↗
51. 10.1016/j.colsurfb.2020.11077810.1016/j.colsurfb.2020.110778 ↗
52. 10.1021/ac504230j10.1021/ac504230j ↗
53. 10.22270/ajprd.v7i2.48210.22270/ajprd.v7i2.482 ↗
54. 10.1007/978-1-59259-739-0_610.1007/978-1-59259-739-0_6 ↗
55. 10.1093/ajcp/28.1.5610.1093/ajcp/28.1.56 ↗